Meghana K Padwal1, Mohsin Murshid2, Prachee Nirmale3, R R Melinkeri4. 1. Professor, Department of Biochemistry, Bharati Vidyapeeth University Medical College , Pune, India . 2. Student, Bharati Vidyapeeth University Medical College , Pune, India . 3. Junior Resident, Department of Biochemistry, Bharati Vidyapeeth University Medical College , Pune, India . 4. Professor and Head, Department of Biochemistry, Bharati Vidyapeeth University Medical College , Pune, India .
Abstract
INTRODUCTION: The impact of CVDs and Type II DM is increasing over the last decade. It has been estimated that by 2025 their incidence will double. Ferritin is one of the key proteins regulating iron homeostasis and is a widely available clinical biomarker of iron status. Some studies suggest that prevalence of atherosclerosis and insulin resistance increases significantly with increasing serum ferritin. Metabolic syndrome is known to be associated with increased risk of atherosclerosis as well as insulin resistance. AIM: The present study was designed to explore the association of serum ferritin levels with metabolic syndrome and insulin resistance. MATERIALS AND METHODS: The present study was prospective, cross sectional. The study protocol was approved by IEC. The study group consisted of 90 participants (50 cases of metabolic syndrome and 40 age and sex matched controls). Diagnosis of metabolic syndrome was done as per NCEP ATP III criteria. Estimation of serum Ferritin and Insulin was done by Chemiluminescence Immunoassay (CLIA) while Glucose by Glucose Oxidase and Peroxidase (GOD-POD) method. Insulin Resistance was calculated by HOMA IR score. STATISTICAL ANALYSIS: Data obtained was statistically analysed by using student t-test. RESULTS: We found statistically significant rise in the levels of serum ferritin (p=<0.001), glucose (p=<0.001), insulin (p=<0.001) and HOMA IR score (p=<0.0001) in cases of metabolic syndrome as compared with controls. CONCLUSION: High serum ferritin levels though within normal range are significantly associated with both metabolic syndrome and insulin resistance.
INTRODUCTION: The impact of CVDs and Type II DM is increasing over the last decade. It has been estimated that by 2025 their incidence will double. Ferritin is one of the key proteins regulating iron homeostasis and is a widely available clinical biomarker of iron status. Some studies suggest that prevalence of atherosclerosis and insulin resistance increases significantly with increasing serum ferritin. Metabolic syndrome is known to be associated with increased risk of atherosclerosis as well as insulin resistance. AIM: The present study was designed to explore the association of serum ferritin levels with metabolic syndrome and insulin resistance. MATERIALS AND METHODS: The present study was prospective, cross sectional. The study protocol was approved by IEC. The study group consisted of 90 participants (50 cases of metabolic syndrome and 40 age and sex matched controls). Diagnosis of metabolic syndrome was done as per NCEP ATP III criteria. Estimation of serum Ferritin and Insulin was done by Chemiluminescence Immunoassay (CLIA) while Glucose by Glucose Oxidase and Peroxidase (GOD-POD) method. Insulin Resistance was calculated by HOMA IR score. STATISTICAL ANALYSIS: Data obtained was statistically analysed by using student t-test. RESULTS: We found statistically significant rise in the levels of serum ferritin (p=<0.001), glucose (p=<0.001), insulin (p=<0.001) and HOMA IR score (p=<0.0001) in cases of metabolic syndrome as compared with controls. CONCLUSION: High serum ferritin levels though within normal range are significantly associated with both metabolic syndrome and insulin resistance.
Authors: K S Reddy; D Prabhakaran; V Chaturvedi; P Jeemon; K R Thankappan; L Ramakrishnan; B V M Mohan; C S Pandav; F U Ahmed; P P Joshi; R Meera; R B Amin; R C Ahuja; M S Das; T M Jaison Journal: Bull World Health Organ Date: 2006-06-21 Impact factor: 9.408
Authors: A Soto González; D Bellido Guerrero; M Buño Soto; S Pértega Díaz; M Martinez-Olmos; O Vidal Journal: Eur J Clin Nutr Date: 2006-02-22 Impact factor: 4.016
Authors: Päivi Hämäläinen; Juha Saltevo; Hannu Kautiainen; Pekka Mäntyselkä; Mauno Vanhala Journal: Diabetol Metab Syndr Date: 2014-10-26 Impact factor: 3.320
Authors: Anna Walentukiewicz; Anna Lysak-Radomska; Joanna Jaworska; Krzysztof Prusik; Katarzyna Prusik; Jakub Antoni Kortas; Marcin Lipiński; Anna Babinska; Jedrzej Antosiewicz; Ewa Ziemann Journal: Int J Environ Res Public Health Date: 2018-09-20 Impact factor: 3.390